Annual report
9273.TEDINET S100RY37
Period2022-07-01 → 2023-06-30
Filed2023-09-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100S3N2 (2023-10-31).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥17.8bn | 2020-07-01 → 2021-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.0bn | 2019-07-01 → 2020-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥15.2bn | 2018-07-01 → 2019-06-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.2bn | 2022-07-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2020-07-01 → 2021-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2019-07-01 → 2020-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2018-07-01 → 2019-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2020-07-01 → 2021-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2019-07-01 → 2020-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥654m | 2018-07-01 → 2019-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥28.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥26.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥24.8bn | at 2021-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥22.9bn | at 2020-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥22.1bn | at 2019-06-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.5bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥7.6bn | at 2022-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥20.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥18.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥16.7bn | at 2021-06-30d | Cons. | Net assets |
| Net assets / equity | ¥14.9bn | at 2020-06-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥13.4bn | at 2019-06-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2021-06-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2020-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.3bn | at 2019-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.1bn | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.3bn | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥385m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥304m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥477m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥223m | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥547m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥244m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥812m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥805m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥679m | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥557m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥816m | 2018-07-01 → 2019-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.94 | 2020-07-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.05 | 2019-07-01 → 2020-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.5 | 2018-07-01 → 2019-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥528.12 | at 2023-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥471.14 | at 2022-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥421.61 | at 2021-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥376.48 | at 2020-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥338.45 | at 2019-06-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.3% | at 2021-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.1% | at 2020-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2019-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 13.6% | 2022-07-01 → 2023-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2021-07-01 → 2022-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2020-07-01 → 2021-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.3% | 2019-07-01 → 2020-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2018-07-01 → 2019-06-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 297 | at 2023-06-30 | Cons. | Number of employees |
| Employees | 303 | at 2022-06-30 | Cons. | Number of employees |
| Employees | 303 | at 2021-06-30d | Cons. | Number of employees |
| Employees | 296 | at 2020-06-30d | Cons. | Number of employees |
| Employees | 310 | at 2019-06-30d | Cons. | Number of employees |
| Revenue | ¥1.1bn | 2022-07-01 → 2023-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥704m | 2021-07-01 → 2022-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥638m | 2020-07-01 → 2021-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥628m | 2019-07-01 → 2020-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥2.1bn | 2018-07-01 → 2019-06-30d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥511m | 2022-07-01 → 2023-06-30 | Standalone | Operating income |
| Operating income | ¥86m | 2021-07-01 → 2022-06-30 | Standalone | Operating income |
| Ordinary income | ¥515m | 2022-07-01 → 2023-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥89m | 2021-07-01 → 2022-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥78m | 2020-07-01 → 2021-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥142m | 2019-07-01 → 2020-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2018-07-01 → 2019-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥515m | 2022-07-01 → 2023-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥89m | 2021-07-01 → 2022-06-30 | Standalone | Income before income taxes |
| Net income | ¥493m | 2022-07-01 → 2023-06-30 | Standalone | Profit loss |
| Net income | ¥95m | 2021-07-01 → 2022-06-30 | Standalone | Profit loss |
| Net income | ¥76m | 2020-07-01 → 2021-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥160m | 2019-07-01 → 2020-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.5bn | 2018-07-01 → 2019-06-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥11.4bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥11.9bn | at 2022-06-30 | Standalone | Assets |
| Total assets | ¥12.1bn | at 2021-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.1bn | at 2020-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.9bn | at 2019-06-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.1bn | at 2023-06-30 | Standalone | Liabilities |
| Total liabilities | ¥1.7bn | at 2022-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥10.3bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-06-30 | Standalone | Net assets |
| Net assets / equity | ¥10.6bn | at 2021-06-30d | Standalone | Net assets |
| Net assets / equity | ¥10.8bn | at 2020-06-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥10.9bn | at 2019-06-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2023-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥842m | at 2022-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥12.44 | 2022-07-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.41 | 2021-07-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.93 | 2020-07-01 → 2021-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.04 | 2019-07-01 → 2020-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.94 | 2018-07-01 → 2019-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥12 | 2022-07-01 → 2023-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11 | 2021-07-01 → 2022-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2020-07-01 → 2021-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2019-07-01 → 2020-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2018-07-01 → 2019-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥260.32 | at 2023-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥258.89 | at 2022-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥266.48 | at 2021-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥273.06 | at 2020-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥275.02 | at 2019-06-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 90.4% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.9% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2021-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2020-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.4% | at 2019-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.8% | 2022-07-01 → 2023-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.9% | 2021-07-01 → 2022-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.7% | 2020-07-01 → 2021-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2019-07-01 → 2020-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.6% | 2018-07-01 → 2019-06-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 39,619,980 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,619,980 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,619,980 | at 2021-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,904,995 | at 2020-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,904,995 | at 2019-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 21 | at 2023-06-30 | Standalone | Number of employees |
| Employees | 22 | at 2022-06-30 | Standalone | Number of employees |
| Employees | 22 | at 2021-06-30d | Standalone | Number of employees |
| Employees | 20 | at 2020-06-30d | Standalone | Number of employees |
| Employees | 17 | at 2019-06-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-07-01 → 2023-06-30 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2022-07-01 → 2023-06-30 | ¥4m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | segment assets | at 2023-06-30 | ¥514m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-06-30 | −¥11m |
| Drug Substance Sales Businessreportable segment | capex | 2022-07-01 → 2023-06-30 | ¥50m |
| Drug Substance Sales Businessreportable segment | depreciation | 2022-07-01 → 2023-06-30 | ¥91m |
| Drug Substance Sales Businessreportable segment | employees | at 2023-06-30 | 76 pure |
| Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2023-06-30 | ¥16.0bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2023-06-30 | ¥14.2bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2023-06-30 | ¥1.8bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2023-06-30 | ¥16.8bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2023-06-30 | ¥2.7bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2022-07-01 → 2023-06-30 | ¥360m |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2022-07-01 → 2023-06-30 | ¥597m |
| Pharmaceutical Marketing Businessreportable segment | employees | at 2023-06-30 | 200 pure |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2023-06-30 | ¥7.9bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2023-06-30 | ¥7.9bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2023-06-30 | ¥11.2bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2023-06-30 | ¥1.5bn |
| —segment total | capex | 2022-07-01 → 2023-06-30 | ¥411m |
| —segment total | depreciation | 2022-07-01 → 2023-06-30 | ¥689m |
| —segment total | employees | at 2023-06-30 | 276 pure |
| —segment total | revenue | 2022-07-01 → 2023-06-30 | ¥23.9bn |
| —segment total | revenue external | 2022-07-01 → 2023-06-30 | ¥22.1bn |
| —segment total | revenue intersegment | 2022-07-01 → 2023-06-30 | ¥1.8bn |
| —segment total | segment assets | at 2023-06-30 | ¥28.0bn |
| —segment total | segment profit | 2022-07-01 → 2023-06-30 | ¥4.3bn |
| Reconciling Itemsreconciling | capex | 2021-07-01 → 2022-06-30 | ¥322,000 |
| Reconciling Itemsreconciling | depreciation | 2021-07-01 → 2022-06-30 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2022-06-30 | −¥1.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2022-06-30 | −¥1.9bn |
| Reconciling Itemsreconciling | segment assets | at 2022-06-30 | ¥108m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2022-06-30 | −¥4m |
| Drug Substance Sales Businessreportable segment | capex | 2021-07-01 → 2022-06-30 | ¥34m |
| Drug Substance Sales Businessreportable segment | depreciation | 2021-07-01 → 2022-06-30 | ¥92m |
| Drug Substance Sales Businessreportable segment | revenue | 2021-07-01 → 2022-06-30 | ¥14.7bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2021-07-01 → 2022-06-30 | ¥12.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2021-07-01 → 2022-06-30 | ¥1.9bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2022-06-30 | ¥15.4bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2021-07-01 → 2022-06-30 | ¥2.4bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2021-07-01 → 2022-06-30 | ¥353m |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2021-07-01 → 2022-06-30 | ¥582m |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2021-07-01 → 2022-06-30 | ¥7.5bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2021-07-01 → 2022-06-30 | ¥7.5bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2022-06-30 | ¥10.7bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2021-07-01 → 2022-06-30 | ¥1.4bn |
| —segment total | capex | 2021-07-01 → 2022-06-30 | ¥387m |
| —segment total | depreciation | 2021-07-01 → 2022-06-30 | ¥674m |
| —segment total | revenue | 2021-07-01 → 2022-06-30 | ¥22.2bn |
| —segment total | revenue external | 2021-07-01 → 2022-06-30 | ¥20.4bn |
| —segment total | revenue intersegment | 2021-07-01 → 2022-06-30 | ¥1.9bn |
| —segment total | segment assets | at 2022-06-30 | ¥26.1bn |
| —segment total | segment profit | 2021-07-01 → 2022-06-30 | ¥3.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,295
| Item | Context | Value | Unit |
|---|---|---|---|
| Foreign exchange losses gains ope cf | CurrentYearDuration | 7135000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | Prior1YearDuration | 1015000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | CurrentYearDuration | 1384000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YearDuration | -685585000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYearDuration | -485045000 | JPY |
| Decrease increase in inventories ope cf | Prior1YearDuration | -154932000 | JPY |
| Decrease increase in inventories ope cf | CurrentYearDuration | -171813000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YearDuration | -107169000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | 67793000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1YearDuration | -7956000 | JPY |
| Decrease increase in accounts receivable other ope cf | CurrentYearDuration | -35087000 | JPY |
| Other net ope cf | Prior1YearDuration | -73827000 | JPY |
| Other net ope cf | CurrentYearDuration | 100770000 | JPY |
| Subtotal ope cf | Prior1YearDuration | 3414106000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 4311144000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YearDuration | 6877000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYearDuration | 4257000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YearDuration | -11073000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYearDuration | -7455000 | JPY |
| Proceeds from subsidy ope cf | Prior1YearDuration | 3523000 | JPY |
| Proceeds from subsidy ope cf | CurrentYearDuration | 2463000 | JPY |
| Income taxes paid ope cf | Prior1YearDuration | -1303247000 | JPY |
| Income taxes paid ope cf | CurrentYearDuration | -1573456000 | JPY |
| Settlement package paid ope cf | Prior1YearDuration | -16000000 | JPY |
| Settlement package paid ope cf | CurrentYearDuration | － | JPY |
| Net cash provided by used in operating activities | Prior1YearDuration | 2094186000 | JPY |
| Net cash provided by used in operating activities | CurrentYearDuration | 2736953000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YearDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYearDuration | 929000 | JPY |
| Purchase of noncurrent assets inv cf | Prior1YearDuration | -443521000 | JPY |
| Purchase of noncurrent assets inv cf | CurrentYearDuration | -271633000 | JPY |
| Payments into time deposits inv cf | Prior1YearDuration | -192011000 | JPY |
| Payments into time deposits inv cf | CurrentYearDuration | -198011000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YearDuration | 162010000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYearDuration | 168011000 | JPY |
| Other net inv cf | Prior1YearDuration | -3809000 | JPY |
| Other net inv cf | CurrentYearDuration | -3409000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -477331000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -304113000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -383248000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -349904000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -395443000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -436213000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -31000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | － | JPY |
| Other net fin cf | Prior1YearDuration | -26211000 | JPY |
| Other net fin cf | CurrentYearDuration | -25942000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -804934000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -812059000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 19819000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |